Millennium Management
COYA icon

Millennium Management’s Coya Therapeutics COYA Stock Holding History

Millennium Management’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,837
Closed -$121K – 5809
2025
Q4 		$121K Buy
+20,837
New +$127K ﹤0.01% 5600

Other funds holding COYA

DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Millennium Management's COYA Position: Q1 2026 in Review

Millennium Management sold out of Coya Therapeutics (COYA) in Q1 2026, closing a stake of 20,837 shares — an estimated $121K sold.

Millennium Management first reported a position in COYA in Q4 2025 and held it in 1 quarter. The position peaked at $121K in Q4 2025. 56 funds tracked by Wall St. Rank hold COYA as of Q1 2026.

  • Millennium Management reported no remaining Coya Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 20,837 Coya Therapeutics shares in Q1 2026, an estimated $121K.
  • Millennium Management first reported a position in Coya Therapeutics in Q4 2025 and held it in 1 quarter.
  • Millennium Management's Coya Therapeutics position peaked at $121K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Coya Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.